11-Methoxyasimilobine, also known as 1,11-dimethoxy-2-hydroxynoraporphine, is a serotonin 5-HT2 receptor agonist of the noraporphine family related to the noraporphine alkaloid asimilobine. It is the 11-methoxy derivative of asimilobine.
Whereas asimilobine is a selective, lower-potency, high-efficacy partial agonist of the serotonin 5-HT2C receptor, 11-methoxyasimilobine is a highly potent and selective full agonist of both the serotonin 5-HT2A and 5-HT2C receptors, with approximately 8-fold preferential activation of the serotonin 5-HT2C receptor over the serotonin 5-HT2A receptor. Its () values were 18nM (98%) at the serotonin 5-HT2A receptor and 2.3nM (100%) at the serotonin 5-HT2C receptor. The drug is a biased agonist of the serotonin 5-HT2C receptor, favoring Gq signaling over β-arrestin recruitment by approximately 6.3-fold. It was among the most potent dual serotonin 5-HT2A and 5-HT2C receptor agonists of a large series of assessed noraporphines.
Besides the serotonin 5-HTA and 5-HT2C receptors, the drug also showed weak agonism of the serotonin 5-HT2B receptor, but only at very high concentrations ( = >10,000nM). It showed little activity at a selection of other serotonin receptors.
The chemical synthesis of 11-methoxyasimilobine has been described. A variety of analogues of the drug with similar activity have also been described.
11-Methoxyasimilobine was described in the scientific literature by Wangzhi Qin and colleagues in 2025. It had previously been patented in 2022. There is interest in 11-methoxyasimilobine and related compounds for potential medical use, such as treatment of anxiety, obsessive–compulsive disorder (OCD), and substance use disorders.
See also Noraporphine Asimilobine 11-Chloroasimilobine 2-Hydroxy-11-(2-methylallyl)oxynoraporphine
References